Clinical Trials Logo

Solid Tumors clinical trials

View clinical trials related to Solid Tumors.

Filter by:

NCT ID: NCT00424632 Completed - Solid Tumors Clinical Trials

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.

NCT ID: NCT00420615 Completed - Solid Tumors Clinical Trials

Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies

Start date: December 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the potential inhibitory effects of patupilone on metabolism using midazolam and omeprazole as the respective probe drugs.

NCT ID: NCT00420485 Completed - Solid Tumors Clinical Trials

Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors

Start date: March 2006
Phase: Phase 1
Study type: Interventional

This study will evaluate the Maximum Tolerated Dose and dose limiting toxicity of gimatecan administered orally in patients with advanced solid tumors

NCT ID: NCT00413686 Completed - Solid Tumors Clinical Trials

Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

Start date: December 2006
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety, tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with gemcitabine. The study is sponsored by AstraZeneca.

NCT ID: NCT00413283 Completed - Cancer Clinical Trials

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.

NCT ID: NCT00404521 Terminated - Solid Tumors Clinical Trials

A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors

Start date: August 2005
Phase: Phase 1
Study type: Interventional

Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors.

NCT ID: NCT00391521 Completed - Solid Tumors Clinical Trials

AS703569 Phase I in Patients With Solid Tumours

Start date: August 2006
Phase: Phase 1
Study type: Interventional

This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.

NCT ID: NCT00390936 Completed - Solid Tumors Clinical Trials

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Start date: October 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.

NCT ID: NCT00360867 Terminated - Solid Tumors Clinical Trials

An Open Label Treatment Extension Study of AMG 706

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This is an extension study to provide ongoing treatment with AMG 706 monotherapy for subjects with solid tumors who have completed the planned duration of AMG 706 treatment on a separate Amgen protocol and have been evaluated as having stable disease or better. Subjects who are no longer eligible to continue AMG 706 treatment on a separate Amgen protocol (for reasons other than AMG 706 intolerance), but who are receiving clinical benefit or have the potential to receive clinical benefit from AMG 706 per the investigator are also eligible to participate in this trial.

NCT ID: NCT00359294 Terminated - Lymphoma Clinical Trials

A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma

Start date: May 2006
Phase: Phase 1
Study type: Interventional

Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study. The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended dose (RD) of PM00104, administered intravenously over 1 hour daily for 5 days every 3 weeks (this is considered as 1 cycle) to subjects with advanced malignant solid tumors or lymphoma.